Korn Christian, Balbach Stefan
Analytical Sciences, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.
Analytical Sciences, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.
Eur J Pharm Sci. 2014 Jun 16;57:257-63. doi: 10.1016/j.ejps.2013.08.040. Epub 2013 Sep 11.
In order to select the best candidates for development, physicochemical criteria such as solubility, chemical and physical stability, hygroscopicity, and thermal characteristics need to be evaluated as early as possible and balanced against other important criteria such as pharmacology or pharmacokinetics. It could be shown, that our miniaturized pharmaceutical profiling concept ("100mg approach"), is capable to reliably identify potential development issues of drug candidates, which, therefore, can be approached early on. Salt formation is a well established strategy to improve unfavorable properties, in particular poor solubility. This article describes our stepwise approach on salt screening, including selection criteria, and summarizes the observations we had during compound investigation. Considering a data base of 337 compounds (salts and uncharged substances), experiences with various counterions evaluated over the last 10years are discussed. We realized that salt formation usually improves poor solubility of a given candidate, but this is often at the cost of other attributes being relevant for pharmaceutical development. Surprisingly, in more than 50% of all cases the "free form" was finally selected after carefully weighing all compound characteristics. Therefore, we conclude that an early salt selection strategy is of utmost importance to predict potential development issues and to enable the provision of alternative physical forms. However, salt formation itself is not necessarily the best solution to meet all development requirements. The selection of a free form (acid or base) in combination with advanced formulation strategies should always be considered, sometimes as best compromise.
为了挑选出最适合开发的候选药物,诸如溶解度、化学和物理稳定性、吸湿性以及热特性等物理化学标准需要尽早评估,并与其他重要标准(如药理学或药代动力学)相权衡。结果表明,我们的小型化药物分析概念(“100毫克方法”)能够可靠地识别候选药物的潜在开发问题,因此可以尽早着手解决。盐形成是一种成熟的策略,用于改善不良性质,尤其是溶解度差的问题。本文描述了我们在盐筛选方面的逐步方法,包括选择标准,并总结了我们在化合物研究过程中的观察结果。考虑到一个包含337种化合物(盐类和不带电荷的物质)的数据库,讨论了过去10年中对各种抗衡离子的研究经验。我们意识到,盐形成通常会改善给定候选药物的溶解度差的问题,但这往往是以牺牲其他与药物开发相关的属性为代价的。令人惊讶的是,在所有案例中,超过50%的情况下,在仔细权衡所有化合物特性后,最终选择了“游离形式”。因此,我们得出结论,早期盐选择策略对于预测潜在开发问题和提供替代物理形式至关重要。然而,盐形成本身不一定是满足所有开发要求的最佳解决方案。应始终考虑选择游离形式(酸或碱)并结合先进的制剂策略,有时这是最佳折衷方案。